Moreover, the combined therapy can effectively downregulate the expression of GPX4, SLC7A11, and FSP-1, promote the accumulation of LPO, and enhance the efficacy of HCC ferroptosis. The gene discussed is GPX4; the disease is hepatocellular carcinoma.